Correlation Between Kalray SA and Innate Pharma

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Kalray SA and Innate Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Kalray SA and Innate Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Kalray SA and Innate Pharma, you can compare the effects of market volatilities on Kalray SA and Innate Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Kalray SA with a short position of Innate Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Kalray SA and Innate Pharma.

Diversification Opportunities for Kalray SA and Innate Pharma

-0.04
  Correlation Coefficient

Good diversification

The 3 months correlation between Kalray and Innate is -0.04. Overlapping area represents the amount of risk that can be diversified away by holding Kalray SA and Innate Pharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Innate Pharma and Kalray SA is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Kalray SA are associated (or correlated) with Innate Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Innate Pharma has no effect on the direction of Kalray SA i.e., Kalray SA and Innate Pharma go up and down completely randomly.

Pair Corralation between Kalray SA and Innate Pharma

Assuming the 90 days trading horizon Kalray SA is expected to generate 3.62 times more return on investment than Innate Pharma. However, Kalray SA is 3.62 times more volatile than Innate Pharma. It trades about 0.03 of its potential returns per unit of risk. Innate Pharma is currently generating about 0.01 per unit of risk. If you would invest  121.00  in Kalray SA on October 16, 2024 and sell it today you would lose (37.00) from holding Kalray SA or give up 30.58% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy98.39%
ValuesDaily Returns

Kalray SA  vs.  Innate Pharma

 Performance 
       Timeline  
Kalray SA 

Risk-Adjusted Performance

2 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Kalray SA are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak basic indicators, Kalray SA reported solid returns over the last few months and may actually be approaching a breakup point.
Innate Pharma 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Innate Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong technical indicators, Innate Pharma is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Kalray SA and Innate Pharma Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Kalray SA and Innate Pharma

The main advantage of trading using opposite Kalray SA and Innate Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Kalray SA position performs unexpectedly, Innate Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Innate Pharma will offset losses from the drop in Innate Pharma's long position.
The idea behind Kalray SA and Innate Pharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.

Other Complementary Tools

Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities